The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Abstract
The Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed a practical and standardized neuropathology protocol for the postmortem assessment of dementia and control subjects. The protocol provides neuropathologic definitions of such terms as “definite Alzheimer's disease” (AD), “probable AD,” “possible AD,” and “normal brain” to indicate levels of diagnostic certainty, reduce subjective interpretation, and assure common language. To pretest the protocol, neuropathologists from 15 participating centers entered information on autopsy brains from 142 demented patients clinically diagnosed as probable AD and on eight nondemented patients. Eighty-four percent of the dementia cases fulfilled CERAD neuropathologic criteria for definite AD. As increasingly large numbers of prospectively studied dementia and control subjects are autopsied, the CERAD neuropathology protocol will help to refine diagnostic criteria, assess overlapping pathology, and lead to a better understanding of early subclinical changes of AD and normal aging.
Get full access to this article
View all available purchase options and get full access to this article.
Information & Authors
Information
Published In
Copyright
© 1991 by the American Academy of Neurology.
Publication History
Published online: April 1, 1991
Published in print: April 1991
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup, Journal of Nuclear Medicine, (jnumed.124.268756), (2025).https://doi.org/10.2967/jnumed.124.268756
- Neuropsychological and clinical indicators of Lewy body and Alzheimer's pathology, Journal of Alzheimer's Disease Reports, 9, (2025).https://doi.org/10.1177/25424823241304386
- Comprehensive characterization of the transcriptional landscape in Alzheimer’s disease (AD) brains, Science Advances, 11, 1, (2025).https://doi.org/10.1126/sciadv.adn1927
- Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders, RSC Medicinal Chemistry, (2025).https://doi.org/10.1039/D4MD00576G
- regionalpcs improve discovery of DNA methylation associations with complex traits, Nature Communications, 16, 1, (2025).https://doi.org/10.1038/s41467-024-55698-6
- Posterior hippocampal sparing in Lewy body disorders with Alzheimer’s copathology: An in vivo MRI study, NeuroImage: Clinical, 45, (103714), (2025).https://doi.org/10.1016/j.nicl.2024.103714
- Vascular endothelial growth factor receptor-1 (FLT1) interactions with amyloid-beta in Alzheimer’s disease: A putative biomarker of amyloid-induced vascular damage, Neurobiology of Aging, 147, (141-149), (2025).https://doi.org/10.1016/j.neurobiolaging.2024.12.010
- Hypertension may associate with cerebral small vessel disease and infarcts through the pathway of intracranial atherosclerosis, Neurobiology of Aging, 145, (84-95), (2025).https://doi.org/10.1016/j.neurobiolaging.2024.11.001
- Neuroimaging in dementia, Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease, (213-224), (2025).https://doi.org/10.1016/B978-0-443-19041-4.00070-4
- Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup, Alzheimer's & Dementia, (2025).https://doi.org/10.1002/alz.14338
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.